<DOC>
	<DOCNO>NCT00020111</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose arsenic trioxide treat young patient leukemia lymphoma .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Young Patients With Refractory Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect arsenic trioxide pediatric patient refractory leukemia lymphoma . - Determine maximum tolerate dose drug patient population . - Determine plasma pharmacokinetics drug patient . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord disease ( acute promyelocytic leukemia [ APL ] v non-APL ) . - Stratum I ( APL patient ) : Patients receive standard-dose arsenic trioxide IV 2 hour daily 5 day week 4 week . Treatment continue every 6 week 3 course absence disease progression unacceptable toxicity . - Stratum II ( Non-APL patient ) : Cohorts 3-6 patient receive escalate dos arsenic trioxide ( accord stratum 1 schedule ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient accrue receive treatment arsenic trioxide recommend phase II dose . Leukemia patient strata without progressive disease achieve complete remission first 20 dos may continue receive arsenic trioxide 2 additional week . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A maximum 18 patient accrue stratum I study within 2-3 year . A total 3-30 patient accrue stratum II study within 1-2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm leukemia lymphoma refractory standard curative treatment regimens Measurable evaluable disease No meningeal leukemia lymphoma No HIVrelated lymphoma No lymphoproliferative disease PATIENT CHARACTERISTICS : Age : 2 21 Acute promyelocytic leukemia ( APL ) patient ( stratum I ) must age 2 12 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin normal SGPT le 2 time upper limit normal No significant hepatic dysfunction would preclude study therapy Renal : Creatinine normal ( age adjust ) OR Creatinine clearance least 60 mL/min Potassium , magnesium , calcium least low limit normal ( oral IV supplementation allow ) No significant renal dysfunction would preclude study therapy Cardiovascular : Rate correct QTc interval great 0.48 EKG No significant cardiac dysfunction would preclude study therapy No cardiac disease , include dysrhythmias Pulmonary : No significant pulmonary dysfunction would preclude study therapy Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No persistent grade 3 great sensory motor neuropathy No prior grand mal seizure ( grade 3 great ) within past 2 year febrile seizure ( except patient APL discretion investigator ) No clinically significant unrelated systemic illness would preclude study therapy ( e.g. , serious infection ) HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 week since prior colonystimulating factor ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , epoetin alfa ) No concurrent immunotherapy Chemotherapy : No prior arsenic trioxide At least 2 week since prior chemotherapy ( 4 week nitrosoureas ) recover No concurrent intrathecal chemotherapy except acute promyelocytic leukemia ( APL ) patient experience progressive meningeal leukemia demonstrate benefit arsenic trioxide systemic disease No concurrent anticancer chemotherapy Endocrine therapy : No concurrent steroid ( except corticosteroid retinoic acid syndrome ) Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : Not specify Other : At least 6 month since prior anticonvulsant At least 1 week since prior retinoid therapy No concurrent retinoids No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
</DOC>